Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 1.00 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932690 | 1.00 | S1PR1 (1.00) | S1PR1S1PR5S1PR4CYP2C9FFAR4 | |
| SCHEMBL951026 | 0.84 | S1PR1 (0.74) | S1PR1S1PR5S1PR4 | |
| SCHEMBL947343 | 0.76 | S1PR1 (1.00) | S1PR1S1PR5S1PR4 | |
| SCHEMBL945324 | 0.76 | S1PR1 (1.00) | S1PR1S1PR5S1PR4 | |
| SCHEMBL2016011 | 0.73 | S1PR1 (0.91) | S1PR1S1PR5S1PR4 | |
| SCHEMBL2016035 | 0.73 | S1PR1 (0.91) | S1PR1S1PR5S1PR4 | |
| SCHEMBL2015485 | 0.73 | S1PR1 (0.91) | S1PR1S1PR5S1PR4 | |
| SCHEMBL948995 | 0.73 | S1PR1 (1.00) | S1PR1S1PR5S1PR4 | |
| SCHEMBL2020136 | 0.72 | S1PR1 (1.00) | S1PR1S1PR5S1PR4 | |
| SCHEMBL2016142 | 0.72 | S1PR1 (1.00) | S1PR1S1PR5S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011005295-A1 | MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005295-A1 | MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |